Astellas, Daiichi Move Ahead With Factor Xa Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese pharmas, each in Phase IIb with their oral Factor Xa inhibitors, are behind J&J/Bayer and Bristol/Pfizer, which have Phase III candidates.